JP7101165B2 - 特定の化学的実体、組成物、および方法 - Google Patents

特定の化学的実体、組成物、および方法 Download PDF

Info

Publication number
JP7101165B2
JP7101165B2 JP2019508173A JP2019508173A JP7101165B2 JP 7101165 B2 JP7101165 B2 JP 7101165B2 JP 2019508173 A JP2019508173 A JP 2019508173A JP 2019508173 A JP2019508173 A JP 2019508173A JP 7101165 B2 JP7101165 B2 JP 7101165B2
Authority
JP
Japan
Prior art keywords
quinazoline
phenyl
acrylamide
pyridin
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019508173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526550A5 (enExample
JP2019526550A (ja
Inventor
シャンピン チャン，
ヨン－リアン チュー，
Original Assignee
ニューファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューファーマ， インコーポレイテッド filed Critical ニューファーマ， インコーポレイテッド
Publication of JP2019526550A publication Critical patent/JP2019526550A/ja
Publication of JP2019526550A5 publication Critical patent/JP2019526550A5/ja
Priority to JP2022017081A priority Critical patent/JP2022058912A/ja
Application granted granted Critical
Publication of JP7101165B2 publication Critical patent/JP7101165B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
JP2019508173A 2016-08-15 2017-08-14 特定の化学的実体、組成物、および方法 Expired - Fee Related JP7101165B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022017081A JP2022058912A (ja) 2016-08-15 2022-02-07 特定の化学的実体、組成物、および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662375382P 2016-08-15 2016-08-15
US62/375,382 2016-08-15
PCT/US2017/046819 WO2018035061A1 (en) 2016-08-15 2017-08-14 Certain chemical entities, compositions, and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022017081A Division JP2022058912A (ja) 2016-08-15 2022-02-07 特定の化学的実体、組成物、および方法

Publications (3)

Publication Number Publication Date
JP2019526550A JP2019526550A (ja) 2019-09-19
JP2019526550A5 JP2019526550A5 (enExample) 2020-09-03
JP7101165B2 true JP7101165B2 (ja) 2022-07-14

Family

ID=61196987

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019508173A Expired - Fee Related JP7101165B2 (ja) 2016-08-15 2017-08-14 特定の化学的実体、組成物、および方法
JP2022017081A Ceased JP2022058912A (ja) 2016-08-15 2022-02-07 特定の化学的実体、組成物、および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022017081A Ceased JP2022058912A (ja) 2016-08-15 2022-02-07 特定の化学的実体、組成物、および方法

Country Status (7)

Country Link
US (3) US10544106B2 (enExample)
EP (2) EP3497087B1 (enExample)
JP (2) JP7101165B2 (enExample)
CN (1) CN109843858B (enExample)
AU (1) AU2017312561B2 (enExample)
CA (1) CA3033370A1 (enExample)
WO (1) WO2018035061A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016005199B1 (pt) 2013-08-23 2022-02-22 Neupharma, Inc Certos compostos químicos, composições, e métodos
EP3270694A4 (en) 2015-02-17 2018-09-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN110386921A (zh) * 2018-04-23 2019-10-29 南京药捷安康生物科技有限公司 成纤维细胞生长因子受体抑制剂化合物
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
EP3904355B1 (en) * 2019-02-18 2024-11-20 Shenzhen TargetRx, Inc. Substituted fused aromatic ring derivative, composition and use thereof
CA3139018A1 (en) * 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
CN110724143B (zh) * 2019-10-09 2021-03-23 清华大学 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
GB201915831D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
BR112022009881A2 (pt) * 2019-11-22 2022-10-11 Univ California Inibidores de caspase 6 e usos dos mesmos
WO2021102299A1 (en) * 2019-11-22 2021-05-27 The Regents Of The University Of California Caspase 6 inhibitors and uses thereof
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
WO2021198981A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Antiviral compounds and uses thereof
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN115916759B (zh) * 2020-06-19 2025-07-15 泰州红云制药有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用
CN115836070B (zh) * 2020-08-10 2024-08-09 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用
TW202220994A (zh) * 2020-08-17 2022-06-01 大陸商貝達藥業股份有限公司 雙環化合物，包含其的藥物組合物及其用途
WO2022053000A1 (zh) * 2020-09-10 2022-03-17 四川海思科制药有限公司 一种碳环酰胺衍生物及其在医药上的应用
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN113603695B (zh) * 2021-08-05 2022-06-14 青岛恒宁生物科技有限公司 一种取代的嘧啶胺类化合物或其作为农药可接受的盐、组合物及其用途
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN119841806A (zh) * 2023-10-16 2025-04-18 中国医学科学院药物研究所 多取代的喹唑啉类化合物及其制备方法、用途和药物组合物
WO2025212165A1 (en) * 2024-04-05 2025-10-09 Board Of Regents Of The University Of Nebraska Targeted heterobifunctional small molecule proteolysis targeting chimeras
WO2025235874A1 (en) * 2024-05-10 2025-11-13 Schrödinger, Inc. Heterocyclics as egfr inhibitors

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002400A1 (en) 1999-07-02 2001-01-11 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
JP2006502165A (ja) 2002-09-06 2006-01-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド ピラゾロピリジンならびにその作製および使用方法
JP2006520385A (ja) 2003-03-13 2006-09-07 シンタ ファーマスーティカルズ コーポレイション 縮合ピロール化合物
JP2008517978A (ja) 2004-10-29 2008-05-29 テイボテク・フアーマシユーチカルズ・リミテツド Ｈｉｖ阻害性二環式ピリミジン誘導体
WO2009131173A1 (ja) 2008-04-23 2009-10-29 協和発酵キリン株式会社 2-アミノキナゾリン誘導体
WO2010019762A1 (en) 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
WO2010056758A1 (en) 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
WO2013005157A1 (en) 2011-07-05 2013-01-10 Lupin Limited Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer
JP2013507448A (ja) 2009-10-12 2013-03-04 ファーマサイクリクス，インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
JP2013507381A (ja) 2009-10-07 2013-03-04 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
JP2013528164A (ja) 2010-05-26 2013-07-08 石薬集団中奇制薬技術（石家庄）有限公司 アリールアミノプリン誘導体、その調製方法および医薬としての使用
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
CN103554038A (zh) 2013-06-19 2014-02-05 云南大学 多卤代苯腈喹唑啉酮化合物及其制备方法和用途
CN103864792A (zh) 2012-12-12 2014-06-18 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮并环类化合物
JP2014529612A (ja) 2011-08-26 2014-11-13 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
JP2014530194A (ja) 2011-09-14 2014-11-17 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
WO2015022926A1 (ja) 2013-08-12 2015-02-19 大鵬薬品工業株式会社 新規な縮合ピリミジン化合物又はその塩
WO2015069441A1 (en) 2013-10-18 2015-05-14 Medivation Technologies, Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
US20150175601A1 (en) 2013-08-23 2015-06-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2015140566A1 (en) 2014-03-20 2015-09-24 Redx Pharma Plc Pyrazolo-pyrimidines as inhibitors of btk
JP2015533822A (ja) 2012-09-28 2015-11-26 イグニタ、インク． 非定型プロテインキナーゼｃのアザキナゾリン阻害薬
WO2015193740A2 (en) 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
WO2016019233A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN105315283A (zh) 2014-07-22 2016-02-10 成都贝斯凯瑞生物科技有限公司 一种Bruton酪氨酸激酶抑制剂
WO2016110821A1 (en) 2015-01-08 2016-07-14 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
CN105777759A (zh) 2016-04-29 2016-07-20 杭州和正医药有限公司 一种布鲁顿酪氨酸激酶抑制剂
WO2016133935A1 (en) 2015-02-17 2016-08-25 Neupharma, Inc. Certain chemical entities, compositions, and methods

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB587936A (en) 1944-09-05 1947-05-09 Francis Henry Swinden Curd New quinazoline derivatives
GB8515934D0 (en) * 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2241551A1 (en) 1996-02-12 1997-08-14 Rutgers, The State University Of New Jersey Coralyne analogs as topoisomerase inhibitors
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
JP3990061B2 (ja) * 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
AU7031500A (en) 1999-09-23 2001-04-24 Astrazeneca Ab Therapeutic quinazoline compounds
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
FR2959510B1 (fr) 2010-04-28 2013-04-26 Centre Nat Rech Scient Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques
JP6147727B2 (ja) 2011-04-01 2017-06-14 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
WO2013106792A1 (en) 2012-01-13 2013-07-18 Acea Biosciences Inc. Heterocyclic compounds and uses as anticancer agents.
TW201348226A (zh) 2012-02-28 2013-12-01 Amgen Inc 作為ｐｉｍ抑制劑之醯胺
SG11201500125QA (en) 2012-07-11 2015-02-27 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
TW201427958A (zh) 2012-09-14 2014-07-16 Univ Nat Yang Ming 芳基胺取代之嘧啶及喹唑啉及其作為抗癌藥物之用途
CN103936742B (zh) 2013-01-17 2017-05-03 程鹏 含嘌呤基的新型pi3k抑制剂及其制备方法和应用
US9708326B2 (en) 2013-02-25 2017-07-18 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
EP2964638B1 (en) 2013-03-06 2017-08-09 Astrazeneca AB Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
WO2014180524A1 (en) 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
KR102173433B1 (ko) 2013-07-11 2020-11-04 에이시아 바이오사이언시스 인코포레이티드. 키나아제 억제제로써의 피리미딘 유도체
US9840520B2 (en) 2014-05-14 2017-12-12 The Regents Of The University Of Colorado, A Body Corporate Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
CN104086551B (zh) 2014-06-06 2016-09-21 人福医药集团股份公司 化合物及其制备方法和用途
CN105837576B (zh) 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002400A1 (en) 1999-07-02 2001-01-11 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
JP2006502165A (ja) 2002-09-06 2006-01-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド ピラゾロピリジンならびにその作製および使用方法
JP2006520385A (ja) 2003-03-13 2006-09-07 シンタ ファーマスーティカルズ コーポレイション 縮合ピロール化合物
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
JP2008517978A (ja) 2004-10-29 2008-05-29 テイボテク・フアーマシユーチカルズ・リミテツド Ｈｉｖ阻害性二環式ピリミジン誘導体
WO2009131173A1 (ja) 2008-04-23 2009-10-29 協和発酵キリン株式会社 2-アミノキナゾリン誘導体
WO2010019762A1 (en) 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
WO2010056758A1 (en) 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
JP2013507381A (ja) 2009-10-07 2013-03-04 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
JP2013507448A (ja) 2009-10-12 2013-03-04 ファーマサイクリクス，インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
JP2013528164A (ja) 2010-05-26 2013-07-08 石薬集団中奇制薬技術（石家庄）有限公司 アリールアミノプリン誘導体、その調製方法および医薬としての使用
WO2013005157A1 (en) 2011-07-05 2013-01-10 Lupin Limited Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer
JP2014529612A (ja) 2011-08-26 2014-11-13 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
JP2014530194A (ja) 2011-09-14 2014-11-17 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
JP2015533822A (ja) 2012-09-28 2015-11-26 イグニタ、インク． 非定型プロテインキナーゼｃのアザキナゾリン阻害薬
CN103864792A (zh) 2012-12-12 2014-06-18 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮并环类化合物
CN103554038A (zh) 2013-06-19 2014-02-05 云南大学 多卤代苯腈喹唑啉酮化合物及其制备方法和用途
WO2015022926A1 (ja) 2013-08-12 2015-02-19 大鵬薬品工業株式会社 新規な縮合ピリミジン化合物又はその塩
US20150175601A1 (en) 2013-08-23 2015-06-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2015069441A1 (en) 2013-10-18 2015-05-14 Medivation Technologies, Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
WO2015140566A1 (en) 2014-03-20 2015-09-24 Redx Pharma Plc Pyrazolo-pyrimidines as inhibitors of btk
WO2015193740A2 (en) 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
CN105315283A (zh) 2014-07-22 2016-02-10 成都贝斯凯瑞生物科技有限公司 一种Bruton酪氨酸激酶抑制剂
WO2016019233A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016110821A1 (en) 2015-01-08 2016-07-14 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2016133935A1 (en) 2015-02-17 2016-08-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN105777759A (zh) 2016-04-29 2016-07-20 杭州和正医药有限公司 一种布鲁顿酪氨酸激酶抑制剂

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Galeta, Juraj et al.，Single-Step Formation of Pyrimido[4,5-d]pyridazines by a Pyrimidine-Tetrazine Tandem Reaction，Organic Letters，2016年，(2016), 18(15), 3594-3597
Kim, Se-Ho et al.，Discovery of (2S)-1-[4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a Purine-Based Hsp90 Inhibitor，Journal of Medicinal Chemistry，2012年，(2012), 55(17), 7480-7501
New pyrrolo[1,2-c]pyrimidine derivatives，Revue Roumaine de Chimie，1997年，42(1)，11-15
Preparation of some new pyrrolo[1,2-c]pyrimidine derivatives，Revista de Chimie，1983年，(1983), 34(12)，1130-1131
Saravanan, Kappusamy et al.，Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α1-Acid Glycoprotein，Journal of Medicinal Chemistry，2011年，(2011), 54(6), 1847-1859
Shi, Li-Ping et al.，Synthesis and antimicrobial activity of polyhalobenzonitrile quinazolin-4(3H)-one derivatives，Bioorganic & Medicinal Chemistry Letters，2013年，(2013), 23(21), 5958-5963
中西 香爾他，第９章 炭素-炭素二重結合の反応，モリソンボイド有機化学（上），第６版，東京化学同人，1994年，pp 412-433

Also Published As

Publication number Publication date
CN109843858A (zh) 2019-06-04
WO2018035061A1 (en) 2018-02-22
EP4006035A1 (en) 2022-06-01
US20200172495A1 (en) 2020-06-04
JP2022058912A (ja) 2022-04-12
US11208388B2 (en) 2021-12-28
EP4006035B1 (en) 2023-11-22
EP3497087A4 (en) 2020-07-29
US20230043970A1 (en) 2023-02-09
AU2017312561B2 (en) 2022-06-30
CN109843858B (zh) 2023-05-05
US12018002B2 (en) 2024-06-25
US10544106B2 (en) 2020-01-28
EP3497087A1 (en) 2019-06-19
US20180072688A1 (en) 2018-03-15
JP2019526550A (ja) 2019-09-19
CA3033370A1 (en) 2018-02-22
AU2017312561A1 (en) 2019-03-07
EP3497087B1 (en) 2021-11-10

Similar Documents

Publication Publication Date Title
JP7101165B2 (ja) 特定の化学的実体、組成物、および方法
JP6559132B2 (ja) ある特定の化学的実体、組成物および方法
CN113166078B (zh) 2-氧代喹唑啉衍生物作为甲硫氨酸腺苷转移酶2a抑制剂
CN108794411B (zh) 某些化学实体、组合物及方法
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
AU2023258375A1 (en) Pyridylpyridone Compounds
JP2020531528A (ja) イミダゾリジン化合物
HK40009359B (en) Chemical entities, compositions, and methods
HK40009359A (en) Chemical entities, compositions, and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200722

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220704

R150 Certificate of patent or registration of utility model

Ref document number: 7101165

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees